Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma

  • Alexander M.M. Eggermont
  • , Christian U. Blank
  • , Mario Mandala
  • , Georgina V. Long
  • , Victoria G. Atkinson
  • , Stéphane Dalle
  • , Andrew Haydon
  • , Mikhail Lichinitser
  • , Adnan Khattak
  • , Matteo S. Carlino
  • , Shahneen Sandhu
  • , James Larkin
  • , Susana Puig
  • , Paolo A. Ascierto
  • , Piotr Rutkowski
  • , Dirk Schadendorf
  • , Rutger Koornstra
  • , Leonel Hernandez-Aya
  • , Anna Maria Di Giacomo
  • , Alfonsus JM van den Eertwegh
    • Jean Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul C. Lorigan, Robert Lupinacci, Clemens Krepler, Nageatte Ibrahim, Michal Kicinski, Sandrine Marreaud, Alexander C. van Akkooi, Stefan Suciu, Caroline Robert

Research output: Contribution to journal › Article › peer-review

73 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science